June 08, 2023
Two convicted former executives of skin graft biotechnology company MiMedx have agreed to pay nearly $2 million to the U.S. Securities and Exchange Commission to resolve claims they played a role in orchestrating a "pervasive, long-running fraud" that saw the company strike backroom deals with distributors to misstate millions of dollars of revenue in its public filings.
March 28, 2022
A New York federal judge on Monday denied a bid from the former chief financial officer of MiMedx Group Inc. to dismiss him from a U.S. Securities and Exchange Commission suit over a purported scheme to falsely inflate the biotech company's revenue, finding that the agency sufficiently pled a host of claims.
June 22, 2021
A former chief financial officer of MiMedx Group Inc. has asked to be excused from a U.S. Securities and Exchange Commission lawsuit targeting him and two former company executives who were convicted in a parallel criminal case, saying he was unaware of a multipronged scheme to falsely inflate the biotech company's revenue by $9.5 million.
November 26, 2019
Two former top executives of MiMedx Group Inc. on Tuesday were hit with securities fraud charges by New York federal prosecutors over a purported multi-pronged scheme to falsely inflate the biotech company's revenue.